Yjy. Wan et al., Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California, PHARMACOGEN, 11(6), 2001, pp. 489-499
Despite its importance in drug metabolism and disease susceptibility, CYP2D
6 activity and genetic polymorphism have rarely been investigated in Africa
n-American populations. In order to bridge this gap, we examined the genoty
pe and phenotype of the enzyme in 154 African-American (AA) and 143 Caucasi
an (C) normal volunteers. AAs are significantly more likely to possess *17
and *5, but less likely to have *4. Overall, the two groups were similar in
their CYP2D6 activity as measured with dextromethorphan as the probe (meta
bolic ratio 2.21 +/-0.78 for AAs; 2.11 +/-0.86 for Cs; t = 1.02, NS). Two o
f four AAs and six of seven Cs were classified as poor metabolizers and hav
e two nonfunctioning alleles. CYP2D6 activity is determined by *17, *4, *5
and age in AAs (r(2) = 0.33, f = 18.8, P < 0.001) and by *4 and *XN in Cs (
r(2) = 0.14, f = 10.8, P < 0.001). These results support previous findings
demonstrating the importance of *17 in determining CYP2D6 activity in AAs.
Pharmacogenetics 11:489-499 (C) 2001 Lippincott Williams & Wilkins.